Trial · NCT02118584
Results by group59
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 59
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part 1: Percentage of Participants With Clinical Remission as Determined by the Partial Mayo Clinic Score (pMCS) | Part 1 (OLE): Etrolizumab | Baseline | 32.0 | percentage of participants | |
| Part 1: Percentage of Participants With Clinical Remission as Determined by the Partial Mayo Clinic Score (pMCS) | Part 1 (OLE): Etrolizumab | Week 4 | 47.2 | percentage of participants | |
| Part 1: Percentage of Participants With Clinical Remission as Determined by the Partial Mayo Clinic Score (pMCS) | Part 1 (OLE): Etrolizumab | Week 8 | 52.2 | percentage of participants | |
| Part 1: Percentage of Participants With Clinical Remission as Determined by the Partial Mayo Clinic Score (pMCS) | Part 1 (OLE): Etrolizumab | Week 12 | 55.9 | percentage of participants | |
| Part 1: Percentage of Participants With Clinical Remission as Determined by the Partial Mayo Clinic Score (pMCS) | Part 1 (OLE): Etrolizumab | Week 24 | 63.7 | percentage of participants | |
| Part 1: Percentage of Participants With Clinical Remission as Determined by the Partial Mayo Clinic Score (pMCS) | Part 1 (OLE): Etrolizumab | Week 36 | 68.3 | percentage of participants | |
| Part 1: Percentage of Participants With Clinical Remission as Determined by the Partial Mayo Clinic Score (pMCS) | Part 1 (OLE): Etrolizumab | Week 48 | 73.4 | percentage of participants | |
| Part 1: Percentage of Participants With Clinical Remission as Determined by the Partial Mayo Clinic Score (pMCS) | Part 1 (OLE): Etrolizumab | Week 60 | 72.2 | percentage of participants | |
| Part 1: Percentage of Participants With Clinical Remission as Determined by the Partial Mayo Clinic Score (pMCS) | Part 1 (OLE): Etrolizumab | Week 72 | 75.4 | percentage of participants | |
| Part 1: Percentage of Participants With Clinical Remission as Determined by the Partial Mayo Clinic Score (pMCS) | Part 1 (OLE): Etrolizumab | Week 84 | 76.5 | percentage of participants | |
| Part 1: Percentage of Participants With Clinical Remission as Determined by the Partial Mayo Clinic Score (pMCS) | Part 1 (OLE): Etrolizumab | Week 96 | 77.2 | percentage of participants | |
| Part 1: Percentage of Participants With Clinical Remission as Determined by the Partial Mayo Clinic Score (pMCS) | Part 1 (OLE): Etrolizumab | Week 108 | 72.0 | percentage of participants | |
| Part 1: Percentage of Participants With Clinical Remission as Determined by the Partial Mayo Clinic Score (pMCS) | Part 1 (OLE): Etrolizumab | Week 120 | 77.4 | percentage of participants | |
| Part 1: Percentage of Participants With Clinical Remission as Determined by the Partial Mayo Clinic Score (pMCS) | Part 1 (OLE): Etrolizumab | Week 132 | 82.2 | percentage of participants | |
| Part 1: Percentage of Participants With Clinical Remission as Determined by the Partial Mayo Clinic Score (pMCS) | Part 1 (OLE): Etrolizumab | Week 144 | 80.0 | percentage of participants | |
| Part 1: Percentage of Participants With Clinical Remission as Determined by the Partial Mayo Clinic Score (pMCS) | Part 1 (OLE): Etrolizumab | Week 156 | 78.5 | percentage of participants | |
| Part 1: Percentage of Participants With Clinical Remission as Determined by the Partial Mayo Clinic Score (pMCS) | Part 1 (OLE): Etrolizumab | Week 168 | 81.0 | percentage of participants | |
| Part 1: Percentage of Participants With Clinical Remission as Determined by the Partial Mayo Clinic Score (pMCS) | Part 1 (OLE): Etrolizumab | Week 180 | 78.8 | percentage of participants | |
| Part 1: Percentage of Participants With Clinical Remission as Determined by the Partial Mayo Clinic Score (pMCS) | Part 1 (OLE): Etrolizumab | Week 192 | 80.8 | percentage of participants | |
| Part 1: Percentage of Participants With Clinical Remission as Determined by the Partial Mayo Clinic Score (pMCS) | Part 1 (OLE): Etrolizumab | Week 204 | 83.6 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02118584/results